DocWire News Editors

DocwireNews

A study published in Blood Advances assessed patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor (CAR) T-cell therapy and found that while the toxicity profile was manageable, the toxicity burden was high and varied by organ systems.Researchers analyzed organ-specific toxicities and outcomes in 60 patients with DLBCL treated with CD19-directed CAR T-cell therapy during the first year of post-treatment.There were 539 grade &ge;2 and 289 grade &ge;3 toxicities. Common grade &ge;3 toxicities included hematological, metabolic, infectious, and neurological complications, with one-year cumulative incidences of 57.7%, 54.8%, 35.4%, and 18.3%, respectively.Patients with impaired performance status had a higher risk of grade &ge;3 metabolic complications, while elevated lactate dehydrogenase was associated with higher risks of grade &ge;3 neurological and pulmonary toxicities. Furthermore, cytokine release syndrome was correlated with higher incidence of grade &ge;3 metabolic, pulmonary, and neurologic complications. One-year non-relapse mortality was 1.7% and overall survival was 69.0%. Grade &ge;3 pulmonary toxicities were associated with increased mortality.&ldquo;Our study emphasizes the importance of toxicity assessment, which could serve as a benchmark for further research to reduce symptom burdens and improve tolerability in patients treated with CAR T-cells,&rdquo; the researchers concluded.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Toxicity Risks Manageable But High after CD19-Directed CAR T-Cell Therapy for DLBCL

Oncology

A study published in Blood Advances assessed patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor (CAR) T-cell therapy and ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe